{
     "PMID": "8575509",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "19960314",
     "LR": "20141120",
     "IS": "0014-2999 (Print) 0014-2999 (Linking)",
     "VI": "285",
     "IP": "3",
     "DP": "1995 Oct 24",
     "TI": "Effect of alpha 2-adrenergic drugs dexmedetomidine and atipamezole on extracellular amino acid levels in vivo.",
     "PG": "239-46",
     "AB": "alpha 2-Adrenoceptors are known to be involved in a variety of physiological functions and pathological conditions, including epilepsy and the extent of excitotoxin-induced cell death. In this study we evaluated whether selective alpha 2-adrenergic drugs can modulate the release of neurotransmitter amino acids. The effect of the alpha 2-adrenoceptor agonist dexmedetomidine (5 micrograms/kg, s.c.) and the alpha 2-adrenoceptor antagonist atipamezole (0.1 mg/kg and 1 mg/kg, s.c.) on the release of extracellular glutamate, aspartate and gamma-aminobutyric acid (GABA) was studied with microdialysis in the hippocampus of freely moving rats under basal and K(+)-evoked conditions. Atipamezole (1 mg/kg) decreased K(+)-evoked glutamate efflux by 30% compared to the control group (P < 0.05) but did not affect significantly the effluxes of aspartate and GABA. Dexmedetomidine and the lower dose of atipamezole (0.1 mg/kg) did not significantly alter the evoked overflow of amino acids. The results suggest that alpha 2-adrenergic drugs have only modest effects on the K(+)-stimulated overflow of extracellular neurotransmitter amino acids in rat hippocampus.",
     "FAU": [
          "Valtonen, P",
          "Haapalinna, A",
          "Riekkinen, P Sr",
          "Halonen, T"
     ],
     "AU": [
          "Valtonen P",
          "Haapalinna A",
          "Riekkinen P Sr",
          "Halonen T"
     ],
     "AD": "A.I. Virtanen Institute, University of Kuopio, Finland.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article"
     ],
     "PL": "Netherlands",
     "TA": "Eur J Pharmacol",
     "JT": "European journal of pharmacology",
     "JID": "1254354",
     "RN": [
          "0 (Adrenergic alpha-2 Receptor Agonists)",
          "0 (Adrenergic alpha-2 Receptor Antagonists)",
          "0 (Adrenergic alpha-Agonists)",
          "0 (Adrenergic alpha-Antagonists)",
          "0 (Amino Acids)",
          "0 (Imidazoles)",
          "03N9U5JAF6 (atipamezole)",
          "30KYC7MIAI (Aspartic Acid)",
          "3KX376GY7L (Glutamic Acid)",
          "56-12-2 (gamma-Aminobutyric Acid)",
          "MR15E85MQM (Medetomidine)",
          "RWP5GA015D (Potassium)",
          "SY7Q814VUP (Calcium)"
     ],
     "SB": "IM",
     "MH": [
          "*Adrenergic alpha-2 Receptor Agonists",
          "*Adrenergic alpha-2 Receptor Antagonists",
          "Adrenergic alpha-Agonists/*pharmacology",
          "Adrenergic alpha-Antagonists/*pharmacology",
          "Amino Acids/*metabolism",
          "Animals",
          "Aspartic Acid/metabolism",
          "Calcium/physiology",
          "Epilepsy/physiopathology",
          "Extracellular Space/drug effects/*metabolism",
          "Glutamic Acid/metabolism",
          "Hippocampus/anatomy & histology/drug effects/physiology",
          "Imidazoles/*pharmacology",
          "Male",
          "Medetomidine",
          "Microdialysis",
          "Potassium/pharmacology",
          "Rats",
          "Rats, Wistar",
          "Seizures/prevention & control",
          "Spectrometry, Fluorescence",
          "gamma-Aminobutyric Acid/metabolism"
     ],
     "EDAT": "1995/10/24 00:00",
     "MHDA": "2001/03/28 10:01",
     "CRDT": [
          "1995/10/24 00:00"
     ],
     "PHST": [
          "1995/10/24 00:00 [pubmed]",
          "2001/03/28 10:01 [medline]",
          "1995/10/24 00:00 [entrez]"
     ],
     "AID": [
          "001429999500405A [pii]"
     ],
     "PST": "ppublish",
     "SO": "Eur J Pharmacol. 1995 Oct 24;285(3):239-46.",
     "term": "hippocampus"
}